P53 Family: At the Crossroads in Cancer Therapy
Journal:
Current Medicinal Chemistry
Volume:
16
Page:
4328-4344
Author(s):
S. Alsafadi, S. Tourpin, F. Andre, G. Vassal and J-C. Ahomadegbe
HIF Prolyl-4-hydroxylase Interacting Proteins: Consequences for Drug Targeting
Journal:
Current Pharmaceutical Design
Volume:
15
Page:
3886-3894
Author(s):
Roland H. Wenger, Gieri Camenisch, Daniel P. Stiehl and Dorthe M. Katschinski
Heparan Sulfate Proteoglycans, Tumour Progression and the Cancer Stem Cell Niche
Journal:
Current Cancer Therapy Reviews
Volume:
5
Page:
256-260
Author(s):
Larisa M. Haupt and Lyn R. Griffiths
Clinical Development of MET Targeted Therapy For Human Cancer
Journal:
Current Cancer Therapy Reviews
Volume:
5
Page:
261-270
Author(s):
Nima Tirgan, Zhe Tang and Patrick C. Ma
Anti-Tumour Effects of Bisphosphonates - What have we Learned from In Vivo Models?
Journal:
Current Cancer Drug Targets
Volume:
9
Page:
807-823
Author(s):
H. K. Brown and I. Holen
Denosumab: The Era of Targeted Therapies in Bone Metastatic Diseases
Journal:
Current Cancer Drug Targets
Volume:
9
Page:
834-842
Author(s):
D. Santini, M. E. Fratto, B. Vincenzi, N. Napoli, S. Galluzzo, M. Tantardini, A. Abbruzzese, M. Caraglia and G. Tonini
Targeted Therapies in Bone Sarcomas
Journal:
Current Cancer Drug Targets
Volume:
9
Page:
843-853
Author(s):
K. Scotlandi, P. Picci and H. Kovar
Challenging the Current Approaches to Multiple Myeloma-Related Bone Disease: From Bisphosphonates to Target Therapy
Journal:
Current Cancer Drug Targets
Volume:
9
Page:
854-870
Author(s):
P. Tassone, P. Tagliaferri, M. Rossi, T. Calimeri, A. Bulotta, A. Abbruzzese, M. Caraglia and P. Neri
Biological Evidence for the Benefit of Green Tea and EGCG in Arthritis
Journal:
Current Rheumatology Reviews
Volume:
5
Page:
259-265
Author(s):
Salahuddin Ahmed
New Platinum and Ruthenium Complexes - the Latest Class of Potential Chemotherapeutic Drugs - a Review of Recent Developments in the Field
Journal:
Mini-Reviews in Medicinal Chemistry
Volume:
9
Page:
1489-1503
Author(s):
Amr Amin and Michael A. Buratovich